Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

Cost-effectiveness of a 14-gene risk score assay to target adjuvant chemotherapy in early stage non-squamous non-small cell lung cancer.

Roth JA, Billings P, Ramsey SD, Dumanois R, Carlson JJ.

Oncologist. 2014 May;19(5):466-76. doi: 10.1634/theoncologist.2013-0357. Epub 2014 Apr 7.

2.
3.

Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.

Blohmer JU, Rezai M, Kümmel S, Kühn T, Warm M, Friedrichs K, Benkow A, Valentine WJ, Eiermann W.

J Med Econ. 2013;16(1):30-40. doi: 10.3111/13696998.2012.722572. Epub 2012 Sep 11.

PMID:
22966753
4.

Cost-Utility of a Prognostic Test Guiding Adjuvant Chemotherapy Decisions in Early-Stage Non-Small Cell Lung Cancer.

Stenehjem DD, Bellows BK, Yager KM, Jones J, Kaldate R, Siebert U, Brixner DI.

Oncologist. 2016 Feb;21(2):196-204. doi: 10.1634/theoncologist.2015-0162. Epub 2015 Nov 27.

5.

Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.

Ting J, Tien Ho P, Xiang P, Sugay A, Abdel-Sattar M, Wilson L.

Value Health. 2015 Sep;18(6):774-82. doi: 10.1016/j.jval.2015.04.008. Epub 2015 Jun 22.

6.

Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.

Wu B, Chen H, Shen J, Ye M.

Clin Ther. 2011 Oct;33(10):1446-55. doi: 10.1016/j.clinthera.2011.09.016. Epub 2011 Oct 11.

PMID:
21992806
8.

Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.

Brown T, Pilkington G, Bagust A, Boland A, Oyee J, Tudur-Smith C, Blundell M, Lai M, Martin Saborido C, Greenhalgh J, Dundar Y, Dickson R.

Health Technol Assess. 2013 Jul;17(31):1-278. doi: 10.3310/hta17310. Review. Erratum in: Health Technol Assess. 2015 May;17(31):281-2.

9.

The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.

Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, Somerville M, Price A, Stein K.

Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. Review.

10.

Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis.

Joerger M, Matter-Walstra K, Früh M, Kühnel U, Szucs T, Pestalozzi B, Schwenkglenks M.

Ann Oncol. 2011 Mar;22(3):567-74. doi: 10.1093/annonc/mdq431. Epub 2010 Sep 13.

PMID:
20843984
11.

Cost-effectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for non-small cell lung cancer.

Narita Y, Matsushima Y, Shiroiwa T, Chiba K, Nakanishi Y, Kurokawa T, Urushihara H.

Lung Cancer. 2015 Oct;90(1):71-7. doi: 10.1016/j.lungcan.2015.07.006. Epub 2015 Jul 26.

12.

Cost-effectiveness of vinorelbine alone or vinorelbine plus cisplatin for stage IV NSCLC.

Evans WK.

Oncology (Williston Park). 1998 Mar;12(3 Suppl 4):18-25; discussion 25-6.

13.

Modelling the cost-effectiveness of adjuvant lapatinib for early-stage breast cancer.

Candon D, Healy J, Crown J.

Acta Oncol. 2014 Feb;53(2):201-8. doi: 10.3109/0284186X.2013.840740. Epub 2013 Oct 14.

PMID:
24125103
14.

Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis.

Westwood M, Joore M, Whiting P, van Asselt T, Ramaekers B, Armstrong N, Misso K, Severens J, Kleijnen J.

Health Technol Assess. 2014 May;18(32):1-166. doi: 10.3310/hta18320. Review.

15.
16.

Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.

Delea TE, Karnon J, Smith RE, Johnston SR, Brandman J, Sung JC, Gross PE.

Am J Manag Care. 2006 Jul;12(7):374-86.

18.

A multigene prognostic assay for selection of adjuvant chemotherapy in patients with T3, stage II colon cancer: impact on quality-adjusted life expectancy and costs.

Hornberger J, Lyman GH, Chien R, Meropol NJ.

Value Health. 2012 Dec;15(8):1014-21. doi: 10.1016/j.jval.2012.07.012. Epub 2012 Nov 7.

19.

Cost-utility analysis of the newly recommended adjuvant chemotherapy for resectable gastric cancer patients in the 2011 Chinese National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Gastric Cancer.

Chongqing T, Liubao P, Xiaohui Z, Jianhe L, Xiaomin W, Gannong C, Siying W, Lihui O, Ziying Z.

Pharmacoeconomics. 2014 Mar;32(3):235-43. doi: 10.1007/s40273-013-0065-2.

PMID:
23709451
20.

Cost-effectiveness of adjuvant FOLFOX and 5FU/LV chemotherapy for patients with stage II colon cancer.

Ayvaci MU, Shi J, Alagoz O, Lubner SJ.

Med Decis Making. 2013 May;33(4):521-32. doi: 10.1177/0272989X12470755. Epub 2013 Jan 11.

Supplemental Content

Support Center